Enterprise Value

3.286B

Cash

479.2M

Avg Qtr Burn

-55.7M

Short % of Float

16.86%

Insider Ownership

2.86%

Institutional Own.

-

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Mirdametinib Details
NF1-associated Plexiform Neurofibromas

Phase 2b

Data readout

Nirogacestat Details
Cancer, Ovarian cancer, recurrent ovarian granulosa cell tumors

Phase 2

Data readout

Phase 1/2

Data readout

Phase 1/2

Data readout

Phase 1/2

Data readout

Phase 1/2

Update

Phase 1b

Data readout

Phase 1b

Data readout